Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Haemophilus influenzae (strain ATCC 51907 / DSM 11...)
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 2.40E+3nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Haemophilus influenzae (strain ATCC 51907 / DSM 11...)
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 2.00E+4nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Haemophilus influenzae (strain ATCC 51907 / DSM 11...)
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 1.00E+5nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
Target3-oxoacyl-[acyl-carrier-protein] synthase 3(Haemophilus influenzae (strain ATCC 51907 / DSM 11...)
Quorex Pharmaceuticals
Quorex Pharmaceuticals
Affinity DataIC50: 1.00E+5nMpH: 7.0 T: 2°CAssay Description:The potency of FabH inhibition (IC50) was determined using [3H]- or [14C]-radiolabeled substrates. This was accomplished at fixed concentrations of a...More data for this Ligand-Target Pair
